Professional Media briefs

Share this article:
Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said, and return to Johns Hopkins. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. She was also criticized for letting some author conflicts go undisclosed.

A Columbia University study found that in 2007, 25 out of 32 consultants to medical device firms drawing $1 million-plus compensation failed to reveal those conflicts of interest in journal articles published the following year. The authors called for tougher disclosure policies at medical journals.

The FDA's Division of Drug Marketing, Advertising and Communication hit Baxter with a warning letter for a physician brochure for Aralast NP, expressing concern over “your continued violative promotion of your products” and citing two previous letters.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?